Patients' biologic features at the time of the study
Case . | Lymphocyte count, ×109/L . | CLL cells, % . | Normal B cells, % . | T cells, % . | NK cells, % . | CD4/CD8 ratio . | LGL (morphology), % . | CD38+ cells, % . |
---|---|---|---|---|---|---|---|---|
1 | 1.39 | 3 | 5 | 72 | 7 | 0.52 | 35 | 4 |
2 | 2.1 | 27 | 2.3 | 42 | 21 | 1.9 | 28 | 3 |
3 | 3.16 | 33 | 2.5 | 49 | 10 | 1.78 | 20 | 2 |
4 | 3.5 | 63 | 0.66 | 26 | 5 | 1.8 | 0 | 1 |
5 | 3.86 | 61 | 0.3 | 34 | 1 | 3.25 | 17 | 0 |
6 | 4.0 | 52 | 0.31 | 30 | 8 | 2.5 | 10 | 6 |
7 | 2.53 | NA | NA | NA | NA | NA | NA | 1 |
8 | 1.4 | 44 | 0.9 | 34 | NA | 1.2 | 0 | 1 |
Case . | Lymphocyte count, ×109/L . | CLL cells, % . | Normal B cells, % . | T cells, % . | NK cells, % . | CD4/CD8 ratio . | LGL (morphology), % . | CD38+ cells, % . |
---|---|---|---|---|---|---|---|---|
1 | 1.39 | 3 | 5 | 72 | 7 | 0.52 | 35 | 4 |
2 | 2.1 | 27 | 2.3 | 42 | 21 | 1.9 | 28 | 3 |
3 | 3.16 | 33 | 2.5 | 49 | 10 | 1.78 | 20 | 2 |
4 | 3.5 | 63 | 0.66 | 26 | 5 | 1.8 | 0 | 1 |
5 | 3.86 | 61 | 0.3 | 34 | 1 | 3.25 | 17 | 0 |
6 | 4.0 | 52 | 0.31 | 30 | 8 | 2.5 | 10 | 6 |
7 | 2.53 | NA | NA | NA | NA | NA | NA | 1 |
8 | 1.4 | 44 | 0.9 | 34 | NA | 1.2 | 0 | 1 |
NA indicates not available.